HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites
Table 3
Univariate and multivariate logistic regressions: factors associated with anal (a) and cervical (b) atypical cytologies.
(a) Factors associated with anal atypical cytology
Univariate
Multivariate
OR
95%CI
AOR
95%CI
Age (each year more)
0.953
0.923–0.984
0.964
0.928–1.002
0.065
Exposure categories MSM (versus no MSM)
4.046
1.883–8.696
2.200
0.892–5.426
0.087
CDC C (yes versus no)
0.674
0.296–1.537
0.348
0.489
0.135–1.775
0.277
HAART (versus naive)
0.440
0.219–0.881
0.549
0.195–1.542
0.255
Nadir CD4+ T cells (each unit more)
1.000
0.998–1.002
0.945
0.999
0.996–1.001
0.355
HPV infection
HPV negative
Ref
Ref
LR versus HPV negative
2.731
0.973–8.257
2.830
2.222–17.036
0.139
HR versus HPV negative
5.233
2.078–13.175
3.479
3.543–20.467
MSM: men who have sex with men; CDC C: AIDS classification according to Atlanta CDC 1993; HAART: highly active antiretroviral therapy; LR: low-risk genotypes; HR: high-risk genotypes.
(b) Factors associated with cervical atypical cytology
Univariate
Multivariate
OR
95%CI
AOR
95%CI
Age (each year more)
1.000
0.954–1.048
0.992
0.975
0.907–1.047
0.484
Exposure categories Heterosexual (versus others)
4.046
1.883–8.696
0.0001
3.332
0.782–14.200
0.104
CDC C (yes versus no)
1.315
0.470–3.679
0.502
2.219
0.445–11.066
0.331
HAART (versus naive)
0.556
0.130–2.383
0.429
0.298
0.030–2.941
0.300
Nadir CD4+ T cells (each unit more)
1.002
0.998–1.005
0.367
1.000
0.996–1.004
0.990
HPV infection
HPV negative
Ref
Ref
LR versus HPV negative
10.800
2.452–47.568
0.002
17.999
2.748–117.9
0.003
HR versus HPV negative
18.857
4.864–73.109
0.0001
26.863
5.195–138.622
0.0001
CDC C: AIDS classification according to Atlanta CDC 1993; HAART: highly active antiretroviral therapy; LR: low-risk genotypes; HR: high-risk genotypes.
